Impact of Mulberry Leaf on Type 2 Diabetes (Mul-DM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00795704
Recruitment Status : Completed
First Posted : November 21, 2008
Results First Posted : August 9, 2012
Last Update Posted : August 9, 2012
Information provided by (Responsible Party):
Daniel Riche, University of Mississippi Medical Center

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Type 2 Diabetes
Interventions: Drug: Mulberry Leaf Extract
Drug: Placebo

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruted from April 2008 - Feb 2010 in University of Mississippi Cardiometabolic clinic.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Two week placebo run-in

Reporting Groups
Placebo Control Group
Mulberry Leaf Extract 500 mg #2 capsules three times daily

Participant Flow:   Overall Study
    Placebo   Mulberry Leaf Extract
STARTED   12   12 
COMPLETED   8   9 
Withdrawal by Subject                3                2 
Adverse Event                1                1 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Placebo Control Group
Mulberry Leaf Extract 500 mg #2 capsules three times daily
Total Total of all reporting groups

Baseline Measures
   Placebo   Mulberry Leaf Extract   Total 
Overall Participants Analyzed 
[Units: Participants]
 12   12   24 
[Units: Participants]
<=18 years   0   0   0 
Between 18 and 65 years   11   12   23 
>=65 years   1   0   1 
[Units: Years]
Mean (Standard Deviation)
 56  (7)   57.3  (5.5)   56.7  (6.2) 
[Units: Participants]
Female   8   8   16 
Male   4   4   8 
Region of Enrollment 
[Units: Participants]
United States   12   12   24 

  Outcome Measures

1.  Primary:   Hemoglobin A1C   [ Time Frame: 3 month minus baseline ]

2.  Secondary:   Number of Participants With Adverse Drug Reactions, Abnormal Metabolic Panel Levels, or Abnormal Liver Enzyme Levels   [ Time Frame: Baseline, 1 month, and 3 months ]

3.  Secondary:   Change From Baseline in Self-Monitoring Blood Glucose (SMBG) Averages   [ Time Frame: Baseline and 3 months ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Daniel Riche
Organization: University of Mississippi Medical Center
phone: 601-984-2640

Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: Daniel Riche, University of Mississippi Medical Center Identifier: NCT00795704     History of Changes
Other Study ID Numbers: 2008-0053
First Submitted: November 19, 2008
First Posted: November 21, 2008
Results First Submitted: April 16, 2012
Results First Posted: August 9, 2012
Last Update Posted: August 9, 2012